Intellect Neurosciences Inc. (fka ILNS)

[cablejohn]

Been looking into TauC3 and TOC-1 and in case you did not know, They are not the cure but a tool. (I admit ignorance of this fact)

Our study, that WE care about is;
The LaFerla study Is for: in vivo (living) proof of concept studies for its monoclonal antibody, TauC3.
In a preclinical model of Alzheimer's disease. Chain Stated that "Intellect recently completed additional in vitro (Tissue) characterization of the TauC3 antibody, which was demonstrated to have a high affinity for delta tau,"
Translation: LaFerla's study seeks to determine if TauC3 CAN be used on living tissue (in vivo,~ Latin; Within the Living) which is of course a very big honking deal!
As we all know on this study ZERO has been reported, however time passes and others were using TauC3..

following study (in vitro) conclusion, the study reports that;Phosphorylation of tau protein at the carboxyl terminus may be among the earliest tau events, and it occurs prior to the apparition of the classical fibrillar structure. Finally, this data validates PHF-1 as an efficient marker for AD cytopathology following the progression of tau aggregation into NFT.
The upshot here is TauC3 was used to "highlite" a marker. TauC3 was and is being used for study's in vitro.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24033439

PHD is a protein that in humans is encoded by the PHF1 gene
Link; http://en.wikipedia.org/wiki/PHF1

The following is to show the use as markers of TauC3 and TOC-1
TauC3:
Immunohistochemistry for modified tau [phosphorylated at Ser199-202 -Thr205 (AT8) and Ser396-404 (PHF-1) or truncated at D421 (TauC3) and E391 (MN423)] was performed on paraffin-embedded human brain sections. Double immunofluorescence for phosphorylated and truncated tau was used to detect intensity and distribution of tau immunoreactivity, and provided detailed characterization of NFT pathology.

SAME LINK AGAIN; http://www.ncbi.nlm.nih.gov/pubmed/24033439

TOC-1:
This characterization of the TOC1 antibody further supports its potential as a powerful biochemical tool that can be used to better investigate the involvement of tau in neurodegenerative diseases.
LINK (2013); http://www.ncbi.nlm.nih.gov/pubmed/23979027#

There are many Tau Monoclonal antibodys avalable. naturally there is only one TauC3, made for a very specific purpose.
LINK;http://search.crpinc.com/?q=TAU&gclid=CNK23Ynt5LoCFchQ7Aod3W4Anw
I am sure ILNS gets some revenue from sales but more importantly TauC3 IS available for researchers to use and is easily obtainable....